PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel.\', \'Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, United States.\', \'Clalit Health Services, Southern District and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.\', \'Sheba Medical Center, Tel-Aviv University, Ramat Gan, Israel.\', \'Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.7554/eLife.68165e68165
?:hasPublicationType
?:journal
  • eLife
is ?:pmid of
?:pmid
?:pmid
  • 34313216
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.121
?:rankingScore_hIndex
  • 74
?:title
  • Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all